Merrem iv, Vaborem(meropenem)
Meropenem, Merrem, Vabomere, Vaborem (meropenem) is a small molecule pharmaceutical. Meropenem was first approved as Merrem iv on 1996-06-21. It is used to treat appendicitis, bacterial infections, bacteroides infections, escherichia coli infections, and fever amongst others in the USA. It has been approved in Europe to treat bacteremia, bacterial infections, pneumonia, respiratory tract infections, and urinary tract infections amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Meropenem, Merrem (discontinued: Meropenem)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Meropenem
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | B. Braun Medical | N-202106 RX | 2015-04-30 | 2 products |
| MEROPENEM | HQ Specialty Pharma | N-215212 RX | 2023-07-26 | 1 products, RLD, RS |
| MERREM IV | Pfizer | N-050706 RX | 1996-06-21 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| meropenem | ANDA | 2025-02-25 |
| meropenem and sodium chloride | New Drug Application | 2024-12-03 |
| meropenem meropenem | ANDA | 2019-05-24 |
| vabomere | New Drug Application | 2024-12-12 |
Indications
FDA
EMA
Show 5 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MEROPENEM / VABORBACTAM, VABOMERE, REMPEX | |||
| 2027-08-29 | GAIN | ||
| 2022-08-29 | NCE | ||
Clinical
Clinical Trials
240 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 2 | 4 | 1 | 1 | 8 |
| Communicable diseases | D003141 | — | — | — | 2 | 4 | 1 | 1 | 8 |
| Intraabdominal infections | D059413 | — | — | — | 2 | 3 | 1 | — | 6 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 3 | 1 | — | 4 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 3 | 1 | — | 4 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | — | 2 | 1 | — | 3 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | 2 | — | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | 1 | — | 1 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | — | — | 1 | — | 1 |
| Toxemia | D014115 | — | — | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | 1 | — | — | 1 |
| Infectious skin diseases | D012874 | — | — | — | — | 1 | — | — | 1 |
| Abscess | D000038 | EFO_0003030 | — | — | — | 1 | — | — | 1 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 1 | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | — | — | — | 1 | 1 |
| Cross infection | D003428 | — | — | — | — | — | — | 1 | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Meropenem |
| INN | meropenem |
| Description | Meropenem is a carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively. It has a role as an antibacterial drug, an antibacterial agent and a drug allergen. It is a carbapenemcarboxylic acid, a pyrrolidinecarboxamide, an alpha,beta-unsaturated monocarboxylic acid and an organic sulfide. |
| Classification | Small molecule |
| Drug class | antibacterial antibiotics, carbapenem derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 96036-03-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL127 |
| ChEBI ID | 43968 |
| PubChem CID | 441130 |
| DrugBank | DB00760 |
| UNII ID | YOP6PX0BAO (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Merrem – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Meropenem
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 46,157 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,820 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use